The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis
Authors:
- Mayara I. PharmD de PaulaMPMayara I. PharmD de Paula
- Sunjae Kmd BaeSBSunjae Kmd Bae
- Ashton A. Ba ShafferASAshton A. Ba Shaffer
- Jacqueline Garonzik-WangJGJacqueline Garonzik-Wang
- Claudia R. FelipeCFClaudia R. Felipe
- Madeleine M. Ba WaldramMWMadeleine M. Ba Waldram
- Allan B. MassieAMAllan B. Massie
- Jose Medina-PestanaJMJose Medina-Pestana
- Dorry L. SegevDSDorry L. Segev
- Helio Tedesco-SilvaHTHelio Tedesco-Silva
- 16 January 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 104 (10) , 2139-2147
Abstract
Background.: Optimizing antithymocyte globulin (ATG) dosage is critical, particularly for high-risk kidney transplant (KT) recipients without cytomegalovirus (CMV) prophylaxis. Methods.: We studied 630 KT recipients with expanded criteria donors or panel reactive antibody ≥50% at Hospital do Rim, Brazil (January 1, 2013 to May 21, 2015) to determine whether a single ATG dose was safe and effective in patients without CMV prophylaxis. Patients received ≥4 doses (1–1.5 mg/kg/per dose) until June 17, 2014, when the induction protocol changed to a single ATG dose (3 mg/kg). We used Cox regression to compare the risk of CMV infection and acute rejection (AR) among KT recipients by ATG dose. Results.: Adjusting for clinical and transplant factors, a single ATG dose was associated with a lower risk of CMV infection (adjusted hazard ratio [aHR]: 0.63; 95% confidence interval [CI], 0.42-0.93; P = 0.02) and a similar risk of AR (aHR: 1.16; 95% CI, 0.47-2.83; P = 0.8), compared to multiple doses. We found no differences in death-censored graft loss (5.0% versus 4.8%, aHR: 1.06; 95% CI, 0.51-2.23; P = 0.9) or mortality (4.7% versus 3.4%; aHR: 1.42; 95% CI, 0.62-3.24; P = 0.4) at 1-year post-KT by ATG dose. Conclusions.: In our study of high-risk KT recipients without CMV prophylaxis, a single ATG dose decreased the risk of CMV infection without increasing the risk of AR or compromising graft or patient survival.Keywords
This publication has 26 references indexed in Scilit:
- Thymoglobulin and Its Use in Renal Transplantation: A ReviewAmerican Journal of Nephrology, 2013
- Cytomegalovirus in Solid Organ TransplantationAmerican Journal of Transplantation, 2013
- Reduced Dose Rabbit Anti-Thymocyte Globulin Induction for Prevention of Acute Rejection in High-Risk Kidney Transplant RecipientsTransplantation, 2009
- Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant RecipientsJournal of the American Society of Nephrology, 2009
- Long-Term Results of Rabbit Antithymocyte Globulin and Basiliximab InductionNew England Journal of Medicine, 2008
- Thymoglobulin Dose Optimization for Induction Therapy in High Risk Kidney Transplant RecipientsTransplantation, 2008
- Effective communication of standard errors and confidence intervalsBiostatistics, 2008
- Rabbit Antithymocyte Globulin versus Basiliximab in Renal TransplantationNew England Journal of Medicine, 2006
- Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantationTransplant International, 2006
- A prospective, randomized, clinical trial of intraoperative versus postoperative thymoglobulin in adult cadaveric renal transplant recipients1Transplantation, 2003